A new blood test is now being developed to improve ovarian cancer diagnosis, with the potential to reduce unnecessary surgery leading to better health outcomes, saving time, stress and money for patients and the healthcare system. Dr Andrew Stephens Hudson Institute of Medical Research, funded by the Ovarian Cancer Research Foundation (OCRF) , has developed a new diagnostic test for ovarian cancer, which is now being commercialised by ASX-bound Australian company Cleo Diagnostics Ltd. Cleo will advance the availability of its cancer diagnostics platform, which is designed to eventually address all ovarian cancer detection markets with specific tests including surgical triage, recurrence, high risk, and early-stage screening.

https://www.miragenews.com/melbourne-team-nears-more-precise-ovarian-1068718/

#miragenews